BioSpace News Archive

Rapid Micro Biosystems, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021.

Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has completed enrollment in EVOGUARD , the registrational Phase 3 clinical trial evaluating EVO100.

Bio-Path Holdings, Inc. today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations.

TRACON Pharmaceuticals (Nasdaq: TCON), announced today that it will report its fourth quarter and full year 2021 financial and operating results after the close of U.S. financial markets on Tuesday, March 15, 2022.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center randomized phase 3 trial.

Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, today announces that it has received a green light for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA).

The All of Us Research Program’s Journey mobile exhibit is traveling across the country to engage communities that have been historically underrepresented in medical research.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 15 new employees.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor, its new Senior Vice President, General Counsel and Chief Compliance Officer.